back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2021-05-18 10:52 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+133,555 vol |
408,555 | |
| Filed 2021-05-18 10:50 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-133,555 vol |
1,550,945 | |
| Filed 2021-05-13 18:07 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-219,880.4958
-23,802 vol $9.24 each |
0 | |
| Filed 2021-05-13 18:06 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$9,044
+23,802 vol $0.38 each |
23,802 | |
| Filed 2021-05-13 18:04 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-9,044.76
-23,802 vol $0.38 each |
1,684,500 | |
| Filed 2021-05-13 18:03 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-176,654.2366
-19,198 vol $9.20 each |
0 | |
| Filed 2021-05-13 18:02 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$7,295
+19,198 vol $0.38 each |
19,198 | |
| Filed 2021-05-13 18:00 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-7,295.24
-19,198 vol $0.38 each |
1,708,302 | |
| Filed 2021-05-13 17:59 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-805,148.75
-87,500 vol $9.20 each |
0 | |
| Filed 2021-05-13 17:57 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$47,250
+87,500 vol $0.54 each |
87,500 | |
| Filed 2021-05-13 17:56 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-13 17:53 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-47,250
-87,500 vol $0.54 each |
1,727,500 | |
| Filed 2021-01-15 17:31 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-294,278.9328
-19,581 vol $15.03 each |
0 | |
| Filed 2021-01-15 17:30 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$10,573
+19,581 vol $0.54 each |
19,581 | |
| Filed 2021-01-15 17:29 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-10,573.74
-19,581 vol $0.54 each |
275,000 | |
| Filed 2021-01-15 17:28 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,507.7209
-5,419 vol $15.04 each |
0 | |
| Filed 2021-01-15 17:27 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$2,926
+5,419 vol $0.54 each |
5,419 | |
| Filed 2021-01-15 17:21 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-2,926.26
-5,419 vol $0.54 each |
294,581 | |
| Filed 2020-12-28 16:32 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
1,815,000 | |
| Filed 2020-12-28 16:31 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
||
| Filed 2020-12-28 16:28 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
||
| Filed 2020-12-18 21:41 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-884,115
-75,000 vol $11.79 each |
0 | |
| Filed 2020-12-18 21:40 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$28,500
+75,000 vol $0.38 each |
75,000 | |
| Filed 2020-12-18 21:39 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-414,143.0424
-35,132 vol $11.79 each |
0 | |
| Filed 2020-12-18 21:39 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$18,971
+35,132 vol $0.54 each |
35,132 | |
| Filed 2020-12-18 21:31 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-28,500
-75,000 vol $0.38 each |
300,000 | |
| Filed 2020-12-18 21:30 Tx date 2020-12-17 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-18,971.28
-35,132 vol $0.54 each |
375,000 | |
| Filed 2020-12-18 21:29 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,857,429.9294
-161,094 vol $11.53 each |
0 | |
| Filed 2020-12-18 21:28 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$86,990
+161,094 vol $0.54 each |
161,094 | |
| Filed 2020-12-18 21:27 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-86,990.76
-161,094 vol $0.54 each |
410,132 | |
| Filed 2020-12-18 21:26 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-335,289.035
-28,774 vol $11.65 each |
0 | |
| Filed 2020-12-18 21:25 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$15,537
+28,774 vol $0.54 each |
28,774 | |
| Filed 2020-12-18 21:23 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-15,537.96
-28,774 vol $0.54 each |
571,226 | |
| Filed 2020-12-18 21:22 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,325,262.9708
-114,007 vol $11.62 each |
0 | |
| Filed 2020-12-18 21:21 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$61,563
+114,007 vol $0.54 each |
114,007 | |
| Filed 2020-12-18 21:20 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-61,563.78
-114,007 vol $0.54 each |
600,000 | |
| Filed 2020-12-18 19:41 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,195,461.372
-185,993 vol $11.80 each |
0 | |
| Filed 2020-12-18 19:40 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$100,436
+185,993 vol $0.54 each |
185,993 | |
| Filed 2020-12-18 19:38 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 19:37 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-100,436.22
-185,993 vol $0.54 each |
714,007 | |
| Filed 2020-12-18 18:09 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+900,000 vol |
900,000 | |
| Filed 2020-12-18 18:07 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 18:06 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
1,215,000 | |
| Filed 2020-12-18 17:54 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
||
| Filed 2020-12-18 17:54 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 17:27 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-12-18 17:25 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-900,000 vol |
||
| Filed 2019-11-12 10:45 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$119,700
+315,000 vol $0.38 each |
2,115,000 | |
| Filed 2019-09-27 15:42 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$972,000
+1,800,000 vol $0.54 each |
1,800,000 | |
| Filed 2019-09-27 09:49 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|